$70.82
4.52% today
Nasdaq, Nov 04, 08:17 pm CET

Corcept Therapeutics Incorporated. Stock price

$74.17
-13.98 15.86% 1M
+0.23 0.31% 6M
+23.78 47.19% YTD
+24.11 48.16% 1Y
+45.65 160.06% 3Y
+56.37 316.69% 5Y
+70.02 1,687.23% 10Y
+69.38 1,448.43% 20Y
Nasdaq, Closing price Mon, Nov 03 2025
+0.70 0.95%

New AI Insights on Corcept Therapeutics Incorporated. Insights AI Insights on Corcept Therapeutics Incorporated.

How does the company make money?
Who are the company’s main competitors?

Key metrics

Basic
Market capitalization
$7.8b
Enterprise Value
$7.5b
Net debt
positive
Cash
$344.7m
Shares outstanding
105.3m
Valuation (TTM | estimate)
P/E
67.4 | 72.9
P/S
10.9 | 8.9
EV/Sales
10.4 | 8.5
EV/FCF
41.4
P/B
12.3
Financial Health
Equity Ratio
80.9%
Return on Equity
20.8%
ROCE
15.5%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$716.1m | $882.8m
EBITDA
$102.9m | $112.5m
EBIT
$102.0m | $117.6m
Net Income
$133.7m | $107.1m
Free Cash Flow
$180.3m
Growth (TTM | estimate)
Revenue
25.7% | 30.8%
EBITDA
-19.9% | -18.3%
EBIT
-20.3% | -14.1%
Net Income
6.1% | -24.1%
Free Cash Flow
46.2%
Margin (TTM | estimate)
Gross
98.4%
EBITDA
14.4% | 12.7%
EBIT
14.2%
Net
18.7% | 12.1%
Free Cash Flow
25.2%
More
EPS
$1.1
FCF per Share
$1.7
Short interest
13.1%
Employees
500
Rev per Employee
$1.4m
Show more

Is Corcept Therapeutics Incorporated. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,031 stocks worldwide.

Corcept Therapeutics Incorporated. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Corcept Therapeutics Incorporated. forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Corcept Therapeutics Incorporated. forecast:

Buy
90%
Hold
10%

Financial data from Corcept Therapeutics Incorporated.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
716 716
26% 26%
100%
- Direct Costs 12 12
37% 37%
2%
704 704
26% 26%
98%
- Selling and Administrative Expenses 352 352
63% 63%
49%
- Research and Development Expense 251 251
15% 15%
35%
103 103
20% 20%
14%
- Depreciation and Amortization 0.99 0.99
80% 80%
0%
EBIT (Operating Income) EBIT 102 102
20% 20%
14%
Net Profit 134 134
6% 6%
19%

In millions USD.

Don't miss a Thing! We will send you all news about Corcept Therapeutics Incorporated. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Corcept Therapeutics Incorporated. Stock News

Neutral
Business Wire
7 days ago
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 4, 2025. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call...
Neutral
Business Wire
16 days ago
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus ...
Neutral
Seeking Alpha
20 days ago
Corcept Therapeutics (CORT) has added Curant Rare as a second specialty pharmacy to handle increased prescription demand for Korlym. Optime Care will discontinue servicing CORT prescriptions due to its preference for exclusive partnerships, causing some market confusion. CORT management and sell-side analysts confirm Curant Health is smoothly processing all new prescription growth, ensuring con...
More Corcept Therapeutics Incorporated. News

Company Profile

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.

Head office United States
CEO Joseph Belanoff
Employees 500
Founded 1998
Website www.corcept.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today